BioSpace News Archive

LinKinVax, a clinical-stage biotechnology company is announcing completion of a €4.350 million seed capital funding round.

Biocept has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.

Vaxcyte, Inc. today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today announced that Dr. Lishan Aklog, Chairman and CEO, will participate in a Fireside Chat at the BTIG MedTech Digital Health, Life Science, and Diagnostics Tools Conference.

PhaseBio Pharmaceuticals, Inc. today announced that the Phase 2b trial of bentracimab has been accepted for presentation in a Late Breaking Clinical Research session at the American College of Cardiology Annual Scientific Session & Expo being held in Washington, D.C., April 2-4, 2022.

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference.

Dyadic International, Inc. and Phibro Animal Health jointly announced that they have entered into an exclusive license agreement for a Phibro targeted disease.

Nanalysis Scientific Corp. announces that on Thursday, February 17, 2021 the Company will put out a corporate update release and Chief Executive Officer Sean Krakiwsky and Chief Financial Officer Luke Caplette will host a conference call at 5:00 P.M. Eastern Time that same day.

AmerisourceBergen, a global healthcare solutions leader, announced that it has reached an agreement to extend its strategic relationship with Cancer Specialists of North Florida, an oncology provider with the largest cancer practice in Jacksonville, specializing in medical oncology, radiation oncology, hematology and diagnostic imaging.

Respira Labs today announces it has closed $2.8 million to continue to develop and produce its chest wearable that uses acoustic resonance to assess lung function and identify changes in lung air volume, which is especially critical for COPD, COVID-19, and asthma patients.